Achilles Therapeutics plc
ACHL
$1.48
$0.010.68%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.97M | 16.33M | 16.48M | 17.01M | 17.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.93M | 70.61M | 70.90M | 75.16M | 71.38M |
| Operating Income | -71.93M | -70.61M | -70.90M | -75.16M | -71.38M |
| Income Before Tax | -66.39M | -63.50M | -64.01M | -69.17M | -75.06M |
| Income Tax Expenses | 485.00K | 466.00K | 424.00K | 491.00K | 27.00K |
| Earnings from Continuing Operations | -66.88 | -63.97 | -64.43 | -69.67 | -75.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.88M | -63.97M | -64.43M | -69.67M | -75.09M |
| EBIT | -71.93M | -70.61M | -70.90M | -75.16M | -71.38M |
| EBITDA | -67.23M | -65.90M | -66.12M | -70.44M | -66.98M |
| EPS Basic | -1.66 | -1.59 | -1.61 | -1.74 | -1.89 |
| Normalized Basic EPS | -1.03 | -0.99 | -1.00 | -1.08 | -1.07 |
| EPS Diluted | -1.66 | -1.59 | -1.61 | -1.74 | -1.89 |
| Normalized Diluted EPS | -1.03 | -0.99 | -1.00 | -1.08 | -1.07 |
| Average Basic Shares Outstanding | 161.25M | 160.89M | 160.44M | 159.89M | 159.22M |
| Average Diluted Shares Outstanding | 161.25M | 160.89M | 160.44M | 159.89M | 159.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
